{"url_path":"/sec/aktx/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1541157/0001493152-26-024446-index.html","accession_number":"0001493152-26-024446","cik":"0001541157","ticker":"AKTX","issuer_name":"Akari Therapeutics Plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1541157/0001493152-26-024446-index.html","primary_entity_key":"0001541157","primary_entity_name":"Akari Therapeutics Plc"},"word_count":42,"has_tables":true,"body_markdown":"**Item\n2. Unregistered Sales of Equity Securities and Use of Proceeds.**\n\n** **\n\nDuring\nthe three months ended March 31, 2026, we did not have any sales of unregistered securities, other than as previously disclosed by us\nin a Current Report on Form 8-K."}